Drugsupdate.com is up for sale. To own one of the most recognized online brands by doctors in India with millions of visitors - click here.

logo image

Doripenem information from DrugsUpdate  

See Available Brands of Doripenem in India

P - Caution when used during pregnancy.
L - Caution when used during Lactation.

Doripenem, an anti-bacterial drug, is indicated for the treatment of drug-resistant, susceptible bacterial infections including complicated intra-abdominal infections, complicated urinary tract infections including pyelonephritis. Empirical therapy should be considered, only if bacterial culture and susceptibility tests are not available. Doripenem injections as a single agent should be used for the treatment of complicated intra-abdominal infections due to Streptococcus intermedius, S. constellatus, E. coli, Pseudomonas aeruginosa, Bacteroides caccae, B. fragilis, B. thetaiotaomicron, B. uniformis, B. vulgatus and Peptostreptococcus micros.
Doripenem injection, as a single agent should be prescribed for the treatment of complicated UTIs including pyelonephritis due to bacterial infections including E. coli, Klebsiella pneumoniae, Acinetobacter baumannii, Proteus mirabilis, P. aeruginosa and concurrent bacteremia.

Pharmacodynamics

Doripenem is a broad-spectrum carbapenem with potent in vitro antibacterial activity against aerobic and anaerobic gram-positive and gram-negative bacteria including Pseudomonas aeruginosa. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins; which in turn inhibits the final transpeptidase step of peptidoglycan synthesis in bacterial cell walls.

Pharmacokinetics

Absorption: Cmax<109>) and AUC are linear over a dose range of 0.5-1 g when given over 1 hr by IV infusion.


Distribution: Average binding to plasma proteins: About 8.1%; independent of plasma drug concentrations. Median V<209>d:16.8 L


Metabolism: Primarily metabolised by dehydropeptidase-I to a microbiologically inactive ring-opened metabolite.


Excretion: Primarily excreted in urine (about 70% as unchanged drug, about 15% as ring-opened metabolite); faeces (≤1%). Mean half-life elimination in healthy adults: About 1 hr.

Doripenem Indications / Doripenem Uses

Complicated intra-abdominal infections (Intravenously).


Complicated urinary tract infections (Intravenously).


Pyelonephritis (Intravenously).


Nosocomial pneumonia (Intravenously).

Doripenem Adverse Reactions / Doripenem Side Effects

Some of the commonly reported adverse events of Doripenem are headache, vaginal discharge, injection-site reaction, diarrhoea, nausea, severe form of itching, watery stools and mild urticaria.


Potentially Fatal: Anaphylaxis, toxic epidermal necrolysis, Stevens-Johnson Syndrome, interstitial pneumonia, seizure.

Precautions

Doripenem treatment is contraindicated in renal and epileptic patients. Patients who are allergic to imipenem, ertapenem, Doripenem, meropenem or any other analogues of penicillin should not use Doripenem.

Special Precautions

May decrease serum concentration of valproic acid to below therapeutic range thus increasing risk of breakthrough seizure; consider alternative antimicrobial agents or additional anti-seizure medications if concurrent usage is necessary. Prolonged use may result in Clostridium difficile-associated diarrhoea (CDAD). May cause development of drug-resistant bacteria when used in the absence of proven or strongly suspected bacterial infection. Renal impairment. Safety and efficacy have not been established in patients <18 yr old.

Other Drug Interactions

Doripenem may interact with other drugs such as valproic acid and probenecid.

Dosage

Intra-abdominal Infection (Adults):
For the treatment of complication forms, a recommended dose of 500 mg, IV, every 8 hours. The treatment should be continued for 5-14 days. In case of clinical response, after 3 days of parenteral therapy, oral therapy can be considered.
 
Urinary Tract Infection (Adults):
For the treatment of complication forms, a recommended dose of 500 mg, IV, every 8 hours. The treatment should be continued for 10-14 days. In case of clinical response, after 3 days of parenteral therapy, oral therapy can be considered.
 
Pyelonephritis (Adults):
For the treatment of complication forms, a recommended dose of 500 mg, IV, every 8 hours. The treatment should be continued for 10-14 days. In case of clinical response, after 3 days of parenteral therapy, oral therapy can be considered.

List of Contraindications

Doripenem and Pregnancy

Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).

Doripenem and Lactation

It is unclear whether the drug could pass through the breast milk to a breast feeding baby. Consult your physician before taking Doripenem, if you are nursing mother.

Doripenem and Children

No information available

Doripenem and Geriatic

No specific information

Doripenem and Other Contraindications

Hypersensitivity; anaphylactic reactions to beta-lactams.

Storage

Store at 20-25°C.


 

Lab interference

Store at 20-25°C.


 

Doripenem brands in India:

Doribax Doriglen Dorinosa Icupen Savador Sudopen

© 2011-2019 DrugsUpdate.com. Disclaimer | Site Map

Feedback
  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to Millions of Visitors instantly.
  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to Millions of Visitors instantly.